studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 365A
(0.05 ng/mL -0.16 ng/mL), (p=0.003 and p=0.02, respectively)).
Following in vitro activation, PD-1 was up-regulated
3.3 fold (p=0.0019) on T cells from AIH patients compared
with HC (1.5 fold). Conclusion: Present study supports an
increased PD-1 mediated immune-regulation in AIH patients.
Furthermore our results support the hypothesis about the presence
of exhausted T cells in autoimmune diseases.
Disclosures:
Henning Gronbaek - Grant/Research Support: Novartis, Ipsen
The following authors have nothing to disclose: Kristian Aarslev, Anders Dige,
Stinne Greisen, Martin Kreutzfeltd, Niels Jessen, Hendrik V. Vilstrup, Bent Deleuran
302
Autoimmune hepatitis type 1 in Dutch elderly versus
younger patients
Martine A. Baven-Pronk 1 , Joanne J. van Silfhout 1 , Aad P. van
den Berg 2 , Henk R. van Buuren 3 , Carin M. Van Nieuwkerk 4 , Bart
van Hoek 1 ; 1 Gastroenterology and Hepatology, Leiden University
Medical Center, Leiden, Netherlands; 2 Gastroenterology and
Hepatology, University Medical Center Groningen, Groningen,
Netherlands; 3 Gastroenterology and Hepatology, Erasmus Medical
Center, Rotterdam, Netherlands; 4 Gastroenterology and Hepatology,
Free University Medical Center, Amsterdam, Netherlands
Background and Aims: Studies on elderly patients with autoimmune
hepatitis (AIH) are limited, of small sample size and
conflicting when it comes to mode of presentation, treatment
and treatment outcome. The aim of this study was to investigate
differences in baseline characteristics, laboratory features,
histology, concomitant autoimmune disease, treatment,
treatment adverse effects and outcome in elderly patients with
AIH type one (age > 60 years at presentation) compared to
younger patients with AIH type one (age < 60 years at presentation)
and compare them to existing data to provide more
insight into AIH in the elderly patient. Patients and Methods:
All patients from 4 academic centres with probable or definite
AIH type I according to the International AIH Group criteria
were included. As much data as possible was retrospectively
retrieved by chart review. Primary endpoints were defined as
remission, liver transplantation or liver related death. Secondary
endpoints were defined as differences in biochemistry and
serology, symptoms, mode of presentation, concurrent autoimmune
diseases, initial and maintenance treatment regimens,
number of switches of therapy, adverse effects of treatment,
achievement of remission, episodes of loss of remission, number
of relapses, cirrhosis at presentation and progression of cirrhosis.
Results: A total of 359 patients were included, 286 (80%)
younger patients, 73 (20%) elderly patients. The young group
presented with significantly higher serum alanine aminotransaminase
(p